ArticleClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases2018
Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009-15.
Article in Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 5 syntheses or guidelines pooled it, 165 citations in OpenAlex.
- Evaluating the risk of dapsone hypersensitivity syndrome in Nepalese Leprosy Patients via HLA-B* 13:01 screening using real-time PCR and comparative meta-analysis of international data.PLoS neglected tropical diseases · 2026Pooled it
- Leprosy relapse after multidrug therapy: Systematic review and meta-analysis.PLoS neglected tropical diseases · 2025Pooled it
- Effectiveness and safety of multidrug therapy containing clofazimine for paucibacillary leprosy and clarithromycin for rifampicin-resistant leprosy: a systematic review and meta-analysis.Frontiers in medicine · 2023Pooled it
- Drug Resistance (Dapsone, Rifampicin, Ofloxacin) and Resistance-Related Gene Mutation Features in Leprosy Patients: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2022Pooled it
- A need for null models in understanding disease transmission: the example of Mycobacterium ulcerans (Buruli ulcer disease).FEMS microbiology reviews · 2022Pooled it
- Assessment of Antimicrobial Resistance in M. leprae Strains From Kiribati.Tropical medicine & international health : TM & IH · 2026Article
- DNA repair pathways in Mycobacterium leprae: insights from reductive genome evolution and therapeutic opportunities.Archives of microbiology · 2026Review
- Accelerating vaccine research and development for skin neglected tropical diseases: A case for leishmaniasis, leprosy, and Buruli ulcer.PLoS neglected tropical diseases · 2026Review
- Rapid Identification of Drug-Resistant Strains of Mycobacterium leprae through qPCR High-Resolution Melt Analysis (HRMA): A High-Throughput and Effective Screening Method.Indian dermatology online journal · 2026Article
- Decoding leprosy: immune response, clinical manifestations and emerging diagnostic approaches.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2025Review
- QUALITY OF LIFE AND STIGMA AMONG PEOPLE LIVING WITH LEPROSY IN SOUTHWESTERN AND NORTH-CENTRAL NIGERIA.Annals of Ibadan postgraduate medicine · 2025Article
- In Vitro and Ex Vivo Evaluation of Rifampicin Cytotoxicity in Human Skin Models.Antibiotics (Basel, Switzerland) · 2025Article
- Classic and new candidate markers for drug resistance in a large cohort of leprosy patients from the Amazon state, Brazil.Antimicrobial agents and chemotherapy · 2025Article
- Pharmacologic properties and inhibitory activity of 6-azasteroids againstMicrobiology spectrum · 2025Article
- Unprecedented in vivo activity of telacebec against Mycobacterium leprae.PLoS neglected tropical diseases · 2025Article
- A Review of the Efficacy, Safety, and Feasibility of Rifamycin-Based Post-Exposure Chemoprophylaxis for Leprosy.Tropical medicine and infectious disease · 2025Review
- Challenges associated with dapsone for leprosy treatment in Indonesia - urgent need for access to alternative antimicrobial drugs.The Lancet regional health. Southeast Asia · 2025Review
- Leprosy research updates: Shaping the future of global health.The Indian journal of medical research · 2025Article
- Unraveling Drug Resistance inInternational journal of microbiology · 2025Review
- Flavin and deazaflavin biosynthesis in mycobacteria: relevance to physiology, implications for drug discovery, MR-1 antigenicity, and vaccine development.Frontiers in immunology · 2025Review
15 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
24 authors at 16 institutions in 10 countries.
Funding
Abstract
objectivesAntimicrobial resistance (AMR) is a priority for surveillance in bacterial infections. For leprosy, AMR has not been assessed because Mycobacterium leprae does not grow in vitro. We aim to obtain AMR data using molecular detection of resistance genes and to conduct a prospective open survey of resistance to antileprosy drugs in countries where leprosy is endemic through a WHO surveillance network.
methodsFrom 2009 to 2015, multi-bacillary leprosy cases at sentinel sites of 19 countries were studied for resistance to rifampicin, dapsone and ofloxacin by PCR sequencing of the drug-resistance-determining regions of the genes rpoB, folP1 and gyrA.
resultsAmong 1932 (1143 relapse and 789 new) cases studied, 154 (8.0%) M. leprae strains were found with mutations conferring resistance showing 182 resistance traits (74 for rifampicin, 87 for dapsone and 21 for ofloxacin). Twenty cases showed rifampicin and dapsone resistance, four showed ofloxacin and dapsone resistance, but no cases were resistant to rifampicin and ofloxacin. Rifampicin resistance was observed among relapse (58/1143, 5.1%) and new (16/789, 2.0%) cases in 12 countries. India, Brazil and Colombia reported more than five rifampicin-resistant cases.
conclusionsThis is the first study reporting global data on AMR in leprosy. Rifampicin resistance emerged, stressing the need for expansion of surveillance. This is also a call for vigilance on the global use of antimicrobial agents, because ofloxacin resistance probably developed in relation to the general intake of antibiotics for other infections as it is not part of the multidrug combination used to treat leprosy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.